Trial Profile
Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2019
Price :
$35
*
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- 26 Mar 2019 Planned End Date changed from 31 Dec 2019 to 31 May 2020.
- 29 Aug 2018 Planned End Date changed from 31 Aug 2019 to 31 Dec 2019.
- 04 Jun 2018 New trial record